CEL-SCI Corporation’s (CVM) Multikine® Product First Comprehensive Immunotherapy Treatment for Cancer
CEL-SCI Corporation (CVM.AMEX) is a biotechnology company involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. Multikine®, the company’s flagship cancer product, will begin global Phase III clinical trial in 2008. Multikine® is the first immunotherapeutic agent being tested as a first-line standard of care cancer treatment. Multikine® is a non-traditional approach to cancer treatment that utilizes the body’s natural ability to fight tumors. Multikine® is also the first of a new class of cancer immunotherapy drugs. It is the first comprehensive immunotherapy and the first immune simulator. This product is unique…